Glaukos Corporation reported record fourth quarter (Q4) net revenues of USD 143.1 million, an increase of 36% compared to Q4 2024. Full year (FY) 2025 net revenues reached USD 507.4 million, up 32% year-over-year. The company attributed its strong performance to growing adoption and utilization of iDose TR, as well as broader global initiatives in its Interventional Glaucoma franchise. Glaukos highlighted sustained growth acceleration, with U.S. Glaucoma net revenues for Q4 at USD 86.4 million. The company remains focused on developing and commercializing novel, dropless platform therapies for chronic eye diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief on February 17, 2026, and is solely responsible for the information contained therein.